2020
Mortality in sickle cell disease: A population‐based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, India
Sheshadri V, Shabeer P, Santhirapala V, Jayaram A, Krishnamurti L, Menon N. Mortality in sickle cell disease: A population‐based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, India. Pediatric Blood & Cancer 2020, 68: e28875. PMID: 33381914, DOI: 10.1002/pbc.28875.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCause of deathCell diseaseMortality rateSeverity of SCDAge groupsAboriginal populationAcute chest syndromePopulation-based studyPercent of deathsCrude mortality rateCommunity-based comprehensive careCause of mortalityCases of deathPaucity of dataCommon monogenic disorderChest syndromeMedian ageHospital recordsSCD patientsAutopsy questionnaireAboriginal communitiesComprehensive careLongitudinal cohortRemote Aboriginal communitiesPrimary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease
Sinha C, Bakshi N, Ross D, Loewenstein G, Krishnamurti L. Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28749-e28749. PMID: 33034129, PMCID: PMC8246626, DOI: 10.1002/pbc.28749.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseasePrimary caregiversSCD complicationsCell transplantationCell diseaseDiminished qualityAutologous hematopoietic progenitor cellsPrimary caregiver reportMajor medical decisionsGene therapyCurative optionSevere complicationsHematopoietic progenitor cellsClinical trialsAcceptable treatmentRecent complicationsComplicationsCaregiver reportsCaregiversProgenitor cellsNormal lifeTransplantationTherapyMedical decisions
2015
Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality
Goel R, Ness P, Takemoto C, Krishnamurti L, King K, Tobian A. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015, 125: 1470-1476. PMID: 25588677, PMCID: PMC4342358, DOI: 10.1182/blood-2014-10-605493.Peer-Reviewed Original ResearchConceptsImmune thrombocytopenic purpuraThrombotic thrombocytopenic purpuraAcute myocardial infarctionPlatelet transfusionsArterial thrombosisVenous thrombosisHigher oddsHospital mortalityThrombocytopenic purpuraGender-adjusted odds ratioPlatelet transfusion practicesNationwide Inpatient SampleConsumptive disordersHIT patientsTransfusion practiceInpatient SampleMyocardial infarctionClinical severityOdds ratioTransfusionThrombosisPrimary mediatorMortalityLittle dataPurpura
2014
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial
Helton KJ, Adams R, Kesler K, Lockhart A, Aygun B, Driscoll C, Heeney M, Jackson S, Krishnamurti L, Miller S, Sarnaik S, Schultz W, Ware R, Investigators F. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood 2014, 124: 891-898. PMID: 24914136, PMCID: PMC4126329, DOI: 10.1182/blood-2013-12-545186.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellBlood Flow VelocityBlood TransfusionBrainCerebrovascular CirculationChildChild, PreschoolFemaleFunctional NeuroimagingHumansHydroxyureaMagnetic Resonance AngiographyMagnetic Resonance ImagingMalePrognosisSecondary PreventionStrokeUltrasonography, Doppler, TranscranialYoung AdultConceptsMagnetic resonance imaging/magnetic resonance angiographyVessel stenosisWorse stenosisMagnetic resonance imaging/Central blinded reviewNew silent infarctTranscranial Doppler examsTransient ischemic attackFuture clinical trialsTranscranial Doppler velocitiesMagnetic resonance angiographySickle cell anemiaHydroxyurea trialIschemic attackRecurrent strokeSilent infarctsCerebrovascular injuryParenchymal injuryChronic transfusionTCD velocitiesSevere baselineDoppler examVascular abnormalitiesClinical trialsIron overload
2013
Comprehensive integrated care for patients with sickle cell disease in a remote aboriginal tribal population in southern India
Nimgaonkar V, Krishnamurti L, Prabhakar H, Menon N. Comprehensive integrated care for patients with sickle cell disease in a remote aboriginal tribal population in southern India. Pediatric Blood & Cancer 2013, 61: 702-705. PMID: 24347362, DOI: 10.1002/pbc.24723.Peer-Reviewed Original ResearchConceptsSickle cell diseaseClinic visitsCare indicatorsCell diseaseHealthcare maintenanceHigh-quality comprehensive careComprehensive clinic visitComprehensive integrated careMedian spleen sizeAcute chest syndromeEpisodes/yearSudden unexplained deathHealthcare deliveryLow-resource settingsQuality comprehensive careChest syndromePenicillin prophylaxisPneumococcal immunizationPuerperal sepsisMesenteric infarctionMedian ageSCD careSevere anemiaActive patientsMedical recordsA double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
Wun T, Soulieres D, Frelinger A, Krishnamurti L, Novelli E, Kutlar A, Ataga K, Knupp C, McMahon L, Strouse J, Zhou C, Heath L, Nwachuku C, Jakubowski J, Riesmeyer J, Winters K. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal Of Hematology & Oncology 2013, 6: 17. PMID: 23414938, PMCID: PMC3585853, DOI: 10.1186/1756-8722-6-17.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnemia, Sickle CellBiomarkers, TumorCell Adhesion MoleculesDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMicrofilament ProteinsMiddle AgedPainPhosphoproteinsPiperazinesPlatelet ActivationPlatelet Aggregation InhibitorsPrasugrel HydrochloridePrognosisPurinergic P2Y Receptor AntagonistsThiophenesYoung AdultConceptsSickle cell diseaseHemorrhagic eventsAdult patientsAntiplatelet agentsSCD patientsCell diseaseP-selectinMedical interventionsMulticenter phase 2 studyPlatelet surface P-selectinMethodsThe primary endpointPlatelet activation biomarkersSafety of prasugrelSerious hemorrhagic eventsPlacebo-controlled studyPhase 2 studyVivo platelet activationSoluble P-selectinSurface P-selectinThienopyridine antiplatelet agentPain ratePrasugrel armPrimary endpointActivation biomarkersStudy arms
2009
Severe Sickle Cell Disease—Pathophysiology and Therapy
Buchanan G, Vichinsky E, Krishnamurti L, Shenoy S. Severe Sickle Cell Disease—Pathophysiology and Therapy. Transplantation And Cellular Therapy 2009, 16: s64-s67. PMID: 19819341, PMCID: PMC2832723, DOI: 10.1016/j.bbmt.2009.10.001.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHematopoietic stem cell transplantationMarrow Transplant Research databaseSickle cell disease pathophysiologyStem cell transplantationCare of patientsModalities of therapyConservative managementInternational BloodCell transplantationTreatment modalitiesChronic illnessCell diseaseSCD manifestationsResearch DatabaseDisease pathophysiologyDiseaseTherapySignificant riskPatientsTransplantationBabiesPsychosocial costsModalitiesMorbidity